Marstacimab
Based on 1 Customer Validation
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.
For research use only. We do not sell to patients.
- Purity: 96.27%
- CAS No.: 1985638-39-8
- Molecular Weight:145.98 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TFPI
In Vitro
Marstacimab (20, 50 and 100 nmol/L) decreases rotational thromboelastometry (ROTEM) corn trypsin (CT) of the whole blood that obtained from haemophilia participants[1]. Marstacimab (16 μg/mL) decreases the lag time and increases thrombin generation of human nonhemophilic plateletpoor plasma samples in vitro[2]. Marstacimab (16 μg/mL) increases the peak thrombin in both hemophilia A and hemophilia B plasma samples in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute bleeding hemophilia A mouse models[2]
-
Dosage:0.5 mg/kg
-
Administration:Intravenous injection, 0.5 mg/kg, once, before tail clip
-
Result:Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda2
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Hela cells labelling TFPI (red) with Marstacimab (anti-TFPI) (HY-P99725). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda2 (HY-P990096). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1985638-39-8
-
Appearance Liquid
-
Molecular Weight 145.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Marstacimab]
-
Synonyms
PF-06741086
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806. [Content Brief]
[2]. Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022 Mar 16;6(2):e12679. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Marstacimab Related Classifications
HY-P99725 Related Classifications
Powered by Bioz